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Abstract: ER niacin combined with simvastatin provides an additional option for achieving 
LDL-C and non-HDL-C goals for cardiovascular prevention, with greater efﬁ  cacy in those 
with triglyceride levels  200 mg/dL. ER niacin 1000 mg combined with simvastatin 20 mg 
reduced LDL-C by 6%, non-HDL-C by 7%, and triglycerides by 13%, and raised HDL-C by 
11% compared to simvastatin 20 mg alone. The 2000 mg dose combined with simvastatin 20 
to 40 mg raised reduced LDL-C by 7% to 24%, non-HDL-C by 16% to 28%, and triglycerides 
by 23% to 34%, and increased HDL-C by 18% to 22% compared to similar dose simvastatin 
therapy. While cardiovascular risk is reduced in proportion to the magnitude of LDL-C lowering, 
the additive beneﬁ  t of raising HDL-C and lowering triglycerides remains to be determined. ER 
niacin-simvastatin is reasonably well tolerated, with a  7% discontinuation rate due to ﬂ  ushing 
in patients who used aspirin or non-steroidal anti-inﬂ  ammatory medications as needed. However, 
drop-out rates were high in both the simvastatin and ER niacin–simvastatin treatment groups in 
both the 24- and 52-week studies. The safety proﬁ  le of the combination appears to be similar to 
that of niacin and simvastatin used as monotherapies. Results of ongoing morbidity/mortality 
trials of ER niacin added to statin therapy are eagerly awaited.
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One extended-release (ER) niacin–simvastatin formulation is available in the US 
and another formulation has been approved in Europe, with approval pending 
in the US. Simcor® (Abbott Laboratories, North Chicago, Illinois, USA) is the 
combination of ER niacin (Niaspan®; Abbott Laboratories, North Chicago, Illinois, 
USA) and simvastatin (Zocor®, Merck Inc., White House Station, New Jersey) 
which was approved by the US Food and Drug Administration (FDA) February, 
2008. ER niacin–simvastatin is indicated to reduce elevated total cholesterol, low 
density lipoprotein cholesterol (LDL-C), apolipoprotein (apo) B, non-high density 
lipoprotein cholesterol (non-HDL-C), or triglycerides, or to increase HDL-C in 
patients with primary hypercholesterolemia and mixed dyslipidemia when treatment 
with simvastatin monotherapy or niacin extended-release monotherapy is consid-
ered inadequate.1 ER niacin–simvastatin is also indicated to reduce triglycerides 
in patients with hypertriglyceridemia (Frederickson type IV hyperlipidemia) when 
treatment with simvastatin monotherapy or niacin ER monotherapy is considered 
inadequate.
Another combination of ER niacin with simvastatin and laropiprant, a compound 
that decreases ﬂ  ushing, MK-524A (previously called Cordaptive®) (Merck, Inc., 
White House Station, New Jersey, USA), was not approved by the FDA in April, 
2008 although it was approved in European countries. The reason for non-approval Vascular Health and Risk Management 2009:5 32
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have not been reported, although is likely related to the 
inclusion of laropiprant. Laropiprant is a potent PGD2 
DP-1 receptor antagonist shown to reduce moderate to severe 
niacin-induced cutaneous vasodilatation without affecting 
lipid-modifying efﬁ  cacy.2 Laropiprant could have harmful 
off-target effects that may counteract beneﬁ  cial effects of 
lipid changes on atherosclerotic disease. Laropiprant is also 
an antagonist of the thromoboxane A2 receptor although little 
effect on platelet aggregation assays or bleeding time has 
been observed.3 The major metabolite of PGD2 is a potent 
endogenous PPARγ activator. Activation of PPARγ via PGD2 
with niacin has been shown to stimulate ABCA1-mediated 
efﬂ  ux of cholesterol from macrophages.4 Whether efforts to 
minimize cutaneous symptoms will inﬂ  uence these pathways 
is unresolved. Moreover, the DP-1 receptor is found in numer-
ous tissues and the speciﬁ  city of laropiprant for epidermal 
Langherhans also remains to be established. It is not clear 
whether approval of the Merck product awaits the results of 
the ongoing Treatment of HDL to Reduce the Incidence of 
Vascular Events (HPS-2 THRIVE), which is comparing the 
effect of ER niacin plus laropiprant–simvastatin to simvastatin 
alone on major cardiovascular events in 20,000 subjects.5
Published data are available only for the ER niacin–
simvastatin coformulation so will be the focus of this review. 
The pharmacology, efﬁ  cacy and safety of ER niacin with 
simvastatin will be presented ﬁ  rst, followed by a discussion 
of the clinical context for this drug combination.
Pharmacology
Niacin exposure from ER niacin–simvastatin has the 
same pharmacologic properties as ER niacin used as 
monotherapy.1 Simvastatin levels were 23% to 41% 
higher from ER niacin–simvastatin than from simvastatin 
as monotherapy. Mechanisms of action, metabolism, and 
excretion are otherwise comparable to those for each drug 
used as monotherapy. Adverse effects of niacin and simv-
astatin therapy are discussed below.
Simvastatin undergoes extensive ﬁ  rst pass metabolism 
and is hydrolyzed to the corresponding active β-hydroxyacid 
form, a potent inhibitor of 3-hydroxy-3-methylglutaryl-
coenzyme A (HMG CoA) reductase, the rate-limiting step 
in cholesterol synthesis.6 HMG-CoA reductase inhibition 
reduces tissue and plasma cholesterol levels, which results in 
upregulation of the expression of LDL receptors in the liver 
and extrahepatic tissues, thereby enhancing removal of the 
cholesterol-rich apolipoproteins LDL-C, very low density 
lipoprotein cholesterol (VLDL-C), and VLDL remnants 
from plasma. Simvastatin is predominantly metabolized 
by the cytochrome P450 isoform (CYP) 3A4, and to a 
lesser degree CYP3A5, CYP2C8, and by glucuronidation. 
Hepatic uptake of simvastatin is facilitated by organic ion 
transporting polypeptide 1B1, polymorphisms of which have 
been associated with increases plasma simvastatin levels 
and propensity to myopathy.7 Simvastatin has 13% urinary 
excretion and 60% biliary excretion. Drug interactions and 
adverse effects of simvastatin are discussed below.
Niacin is a form of vitamin B3 that in pharmacologic 
doses has beneﬁ  cial effects on multiple lipid parameters. 
Niacin undergoes extensive ﬁ  rst pass metabolism in the liver 
where it is rapidly converted to the active form nicotinamide 
adenine dinucleotide (NAD) in the NAD coenzyme system.1 
Niacin is not metabolized through the same pathways as 
statins, and is excreted in urine. Niacin has few important 
drug interactions although it is extensively bound to 
cholestyramine.
Niacin lowers the level of very low density lipoprotein 
cholesterol (VLDL-C), the precursor to LDL-C, through 
a variety of mechanisms, only some of which have been 
elucidated.8,9 Activation of adipocyte G protein-coupled 
nicotinic acid receptor GPR109A (HM74A in humans) 
results in inhibition of hormone-sensitive lipase, reduced 
triglyceride hydrolysis, and reduced flux of free fatty 
acids from adipose to the liver. Decreased fatty acid 
synthesis and esteriﬁ  cation reduces triglyceride synthesis. 
Increased lipoprotein lipase activity may increase the rate of 
chylomicron triglyceride removal from plasma. Reductions 
in intrahepatic triglyceride availability taken together 
with increased catabolism of apolipoprotein B, results in 
decreased assembly of apolipoprotein (apo)-B containing 
proteins VLDL and LDL.10 Increased catabolism of VLDL-C 
also lowers LDL-C levels. Reduced large triglyceride-rich 
VLDL-C levels result in lower levels of small dense LDL-C. 
Niacin raises HDL-C by increasing apo A-I synthesis and 
decreasing HDL-C uptake and removal via the ATP synthase 
β-chain, an HDL/ApoA-I receptor for HDL endocytosis in 
liver cells.10,11 Decreased triglyceride synthesis may also 
increase HDL-C levels. Niacin does not affect the reverse 
cholesterol transport pathway.
Efﬁ  cacy
Three shorter-term efﬁ  cacy and safety trials comparing ER 
niacin–simvastatin to simvastatin monotherapy have been 
published, SEACOAST I and II (24 weeks) and OCEANS 
(52 weeks) (Table 1).12–14 Subjects were selected on the basis 
of having a non-HDL-C above the goal deﬁ  ned in the third 
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Panel (ATP III). About half of subjects were women and most 
were middle aged (median age 58–60 years). On a lead-in of 
either simvastatin 20 mg or 40 mg, median non-HDL-C levels 
were 131 to 165 mg/dL (3.39–4.27 mmol/L), LDL-C levels 
were 99 to 118 mg/dL (2.56–3.06 mmol/L), HDL-C levels were 
41 to 47 mg/dL (1.06–1.22 mmol/L), triglyceride levels 
were 141 to 214 mg/dL (1.59–2.42 mmol/L), and Apo B 
levels were 89 to 103 mg/dL. Adherence rates were 96% 
to 98% in the 24-week SEACOAST studies and 82% in the 
52-week OCEANS study. Drop-out rates were substantial and 
unusually high for this type of shorter-term efﬁ  cacy safety 
trial. However, the rates in the ER niacin – simvastatin groups 
(28%–31% for the 1000 mg doses, 22%–29% for the 2000 mg 
doses) did not differ greatly from the simvastatin monotherapy 
groups (26%–27%) in the SEACOAST studies.
In SEACOAST I, the addition of ER niacin 1000 mg 
to simvastatin 20 mg reduced non-HDL-C by another 7% 
compared to simvastatin 20 mg plus 50 mg of immediate-
release (IR) niacin added with the intention of maintaining 
the blind but without lipid-lowering efﬁ  cacy. LDL-C was 
reduced by 6%, triglycerides by 13%, and Apo B by 10%, 
and increased HDL-C by 11% (Table 1).13 (Note: efﬁ  cacy 
comparisons in the text were calculated as difference from 
the simvastatin comparator arm at the end of the treatment 
period). The addition of ER niacin 2000 mg to simvastatin 
20 mg decreased non-HDL-C by another 16%, LDL-C by 
7%, triglycerides by 23%, and Apo B by 14%, and increased 
HDL-C by 18%. Greater reductions in non-HDL-C were 
observed in those with triglycerides  200 mg/dL (−9% 
on ER niacin 1000 mg and −19% compared to simvastatin 
monotherapy) than those with triglycerides  200 mg/dL 
(−5% for ER niacin 1000 mg and −7% for ER niacin 
2000 mg). A similar blunting of efﬁ  cacy with lower triglyc-
eride levels was also observed for triglycerides (−14% and 
−29% vs −9% and −14%), and Apo B (−11% and −20% vs 
−3% and −6%) but not for HDL-C (+9% and +17% vs +14% 
and +20%). ER niacin–simvastatin appeared to have similar 
efﬁ  cacy in women as in men.
In SEACOAST II, when ER niacin 1000 mg was added 
to simvastatin 40 mg there was no difference in non-HDL-C 
or LDL-C compared to simvastatin 80 mg (with 50 mg IR 
niacin), although HDL-C increased by 14% and triglycerides 
were reduced by 23%.12 However, ER niacin 2000 mg added to 
simvastatin 40 mg had greater efﬁ  cacy for all lipid parameters 
when compared to simvastatin 80 mg. When compared to sim-
vastatin 80 mg, non-HDL-C was reduced by an additional 7%, 
triglycerides by 32%, and Apo B by 10%, and HDL-C was 
increased by 21%, although LDL-C did not differ.12
In the OCEANS study, after a lead-in on simvastatin 
40 mg, subjects were randomized to receive an 8- or 
12-week titration of ER niacin to 2000 mg combined with 
simvastatin 40 mg.14 No difference in tolerability, safety, 
or efﬁ  cacy was found and results were pooled for analysis. 
Compared to baseline after 4 weeks of simvastatin 40 mg 
therapy, at 24 weeks the addition of ER niacin 2000 mg to 
simvastatin 40 mg reduced non-HDL-C by an additional 
22%, LDL-C by 21%, triglycerides by 30%, and apo B 
by 20%, and increased HDL-C by 21% (Table 1). A little 
more than half of subjects completed 52 weeks of follow-
up and slightly greater efﬁ  cacy for all lipid parameters was 
observed. The greater efﬁ  cacy observed in OCEANS was 
similar to that observed in the SEACOAST studies when 
the on-treatment lipid levels on 2000 mg ER niacin were 
compared to baseline levels.
All 3 trials evaluated lipoprotein (a) [Lp(a)]. As shown 
in Table 1, baseline Lp(a) levels ranged from 9 to 24 mg/dL 
(0.32–0.86 μmol/L). Compared to simvastatin 20 or 40 mg 
with 50 mg of immediate-release niacin, the addition of ER 
niacin 1000 mg reduced Lp(a) levels by 9% to 17%, and the 
addition of ER niacin 2000 mg reduced Lp(a) levels by an 
additional 17% to 21%. When compared to the simvastatin 
20 to 40 mg lead-in, Lp(a) reductions of 21% to 29% were 
observed. Ratios of Apo A-I to Apo B increased by 4% to 
16% for the ER niacin 1000 mg groups and by 10% to 30% 
for the ER niacin 2000 mg groups compared to simvastatin 
with 50 mg immediate-release niacin groups. Compared to 
the simvastatin monotherapy lead-in, the ER niacin 2000 mg 
dose increased the Apo A-I/B ratio by 22% to 43%. Com-
mensurate declines of 25% to 33% in the total to HDL-C 
ratio compared to baseline were observed.
The addition of ER niacin 1000 or 2000 mg to simvastatin 
20 or 40 mg did not increase the proportion of subjects 
achieving their NCEP-defined non-HDL-C and LDL-C 
goals compared to simvastatin 20 or 80 mg monotherapy.12,13 
Although not a goal established by ATP III,15 subjects 
receiving ER niacin 1000 or 2000 mg with simvastatin 
40 mg, or ER niacin 2000 mg with simvastatin 20 mg (65%, 
75%, and 70% respectively) were more likely to achieve an 
HDL-C   40 mg/dL (1.04 mmol/L) compared to simvastatin 
20 or 80 mg (45% and 25%, respectively). Achievement of a 
triglyceride level   150 mg/dL (1.69 mmol/L), again not a 
goal established by ATP III, occurred with greater frequently 
with ER niacin 1000 or 2000 mg with simvastatin 40 mg, 
or ER niacin 2000 mg with simvastatin 20 mg, (45%, 65%, 
and 50%, respectively) than with simvastatin 20 or 80 mg 
(30% and 15%, respectively).Vascular Health and Risk Management 2009:5 34
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Table 1 ER niacin–simvastatin trials
Study population Treatment duration Treatment N Adherence
N randomized 
(N end of study)
SEACOAST I13 LDL-C   target + Non-HDL-C 
above goal on simva 20 mg
Median age 58
Men 49 (–58%
24 weeks Simvastatin 20 mg + 
IR niacin 50 mg
Simvastatin 20 mg + 
ER niacin 1000 mg
Simvastatin 20 mg + 
ER niacin 2000 mg
121 (90)
108 (78)
56 (40)
99%
96%
97%
SEACOAST II12 Non-HDL-C above 
goal on simva 40 mg
Median age 60 Men 51%–61%
24 weeks Simvastatin 80 mg + 
IR niacin 50 mg
Simvastatin 40 mg + 
ER niacin 1000 mg
Simvastatin 40 mg + 
ER niacin 2000 mg
123 (90)
118 (82)
102 (80)
98%
98%
98%
N randomized 
(N wk 24; end of study)
OCEANS14 Non-HDL-C above 
goal on simva 40 mg
Mean age 59–60 Men 55%–58%
52 weeks 8 week titration to ER niacin 
2000 mg
12 week titration to ER niacin 
2000 mg
231 (142; 87)
232 (126; 74)
82%
82%
N end of study
ARBITER 268 CHD 7 HDL-C   45 mg/dL
Mean age 67
Men 91%
12 months Simvastatin   20 mg  § + placebo
Simvastatin   20 mg§ + 
ER niacin 1000 mg
80
87
90%–95%
90%–95%
§93.4% received simvastatin. 
No trials comparing ER niacin–simvastatin to placebo 
are available to gauge absolute lipid beneﬁ  ts. It is somewhat 
unclear from the limited data in the 3 trials above whether 
the addition of ER niacin to simvastatin retains the full 
effect of both agents on LDL-C. ER niacin 2000 mg lowered 
LDL-C by 14% in the ER niacin clinical database, and this 
reduction was preserved when added to lovastatin 40 mg 
(Advicor®, Abbott Laboratories, North Chicago, Illinois).25 
It does appear that in patients with non-HDL-C above goals 
on statin therapy, most of the beneﬁ  t should be expected in 
non-HDL-C rather than LDL-C levels, as was observed in the 
study populations of these 3 ER niacin–simvastatin trials.
Adverse effects
Flushing
Niacin-induced flushing of the face and upper body is 
characterized by redness, warmth, tingling, or itching, and 
usually lasts an hour or less. Flushing is related to peak serum 
levels of niacin. ER niacin is absorbed over 8 to 12 hours 
and peak levels are lower than for immediate release niacin.16 
Although the proportion of patients who ﬂ  ushed was about 
the same for ER niacin as for immediate-release niacin, the 
number of ﬂ  ushing episodes was much lower (9 vs 2 ﬂ  ushing 
events) over a 4 week period after 4 weeks on the 1500 mg 
dose.17 In the 2 trials of the ER niacin and simvastatin 20 or 
40 mg, ER niacin–simvastin, about 55% of subjects experi-
enced any ﬂ  ushing with the 1000 mg ER niacin, and up to 
about 65% experienced any ﬂ  ushing with the 2000 mg ER 
niacin dose (Table 2). Serious ﬂ  ushing and ﬂ  ushing resulting 
in discontinuation occurred in only 4 to 7% of those receiv-
ing 1000 mg ER niacin and 6% to 11% of those receiving 
the 2000 mg dose.
Niacin binds to adipocyte and macrophage GPR109A 
(HM74A) to induce release of prostaglandin D2 (PGD2) by 
epidermal Langherhans cells.18 PGD2 acts locally on capillary 
smooth muscle cells via the PGD2 receptor (DP1) to induce 
cutaneous capillary vasdilation. Niacin may also increase 
prostaglandin E2, thromboxane B2, and leukotriene synthesis. 
Pretreatment with aspirin 325 mg or other non-steroidal 
ant-inﬂ  ammatory agents that inhibit prostaglandin release Vascular Health and Risk Management 2009:5 35
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Table 1 (Continued)
Non-HDL-C LDL-C HDL-C Triglyceride Lp(a) Apo B Apo A-I/ B ratio Total/ HDL-C ratio
Baseline after 4 week simvastatin 20 mg lead-in in mg/dL (Median change from simvastatin 20 mg lead-in – ITT)
157 (–7%)
165 (–14%)
160 (–23%)
115 (–7%)
118 (–13%)
112 (–14%)
43 (7%)
41 (18%)
41 (25%)
209 (–15%)
210 (–27%)
214 (–38%)
15 (–8%)
12 (–17%)
9 (–25%)
101 (–4%)
103 (–14%)
96 (–18%)
1.2 (11%)
1.3 (27%)
1.3 (41%)
5 (–10%)
5 (–21%)
5 (31%)
Baseline after 4-week simvastatin 40 mg lead-in in mg/dL (Median change from simvastatin 40 mg lead-in)
131 (–10%) 99 (–13%) 47 (–1%) 141 0% 19 0% 89 (–9%) 1.5 (12%) 3.8 (–5%)
136 (–11%) 105 (–9%) 44 (15%) 147 (–23%) 20 (–17%) 90 (–10%) 1.5 (16%) 4.1 (–16%)
143 (–17%) 109 (–12%) 46 (22%) 156 (–32%) 23 (–21%) 92 (–14%) 1.4 (22%) 4.2 (–25%)
Baseline after 4 week simvastatin 40 mg lead-in in mg/dL (Median change from simvastatin 40 mg lead-in – ITT at 24 weeks 
[only subjects completing 52 weeks])
141 (–23%) 
[–25%]
111 (–22%) 
[–20%]
45 (22%) 
[27%]
145 (–33%) 
[–40%]
24 (–25%) 
[−29%]
94 (–22%)
[−25%]
1.4 (36%) 
[43%]
4.2 (–28%)
[−30%]
141 (–21%) 
[−28%]
110 (–20%) 
[−24%]
45 (20%) 
[25%]
152 (–27%) 
[−34%]
21 (–21%) 
[−25%]
94 (–17%) 
[–26%]
1.4 (36%) 
[43%]
4.2 (–27%) 
[−33%]
Baseline in mg/dL (Change from baseline in mg/dL)
121 (–5%) 91 (–6%) 40 (0%) 172 (–5%) 4.0 (–3%)
115 (–7%) 87 (–2%) 39 (21%) 154 (–13%) 3.95 (–17%)
Non-HDL-C = total cholesterol − HDL-C.
Abbreviations: CHD, coronary heart disease; ER, extended release; IQR, interquartile range; IR, immediate release; ITT, intent to treat; LDL-C, low-density lipoprotein 
cholesterol; Lp(a), lipoprotein (a); Non-HDL-C, non-high-density lipoprotein cholesterol; SR, slow release.
taken 30 to 60 minutes prior to niacin can reduce ﬂ  ushing 
incidence and intensity by 30% to 40%.19,20 Tachyphylaxis 
to PGD2 secretion begins to occur after 1 week of consistent 
dosing and most patients experience a marked diminution 
of ﬂ  ushing after 4 weeks and by 1 year most patients report 
very infrequent or no ﬂ  ushing.16 Niacin less commonly 
causes maculopapular rash and urticaria. Rarely, acanthosis 
nigricans, hyperpigmentation, and dermopathies may 
occur.
Liver
Persistent elevations in hepatic alanine aminotransferase  3 
times the upper limit of normal, the best index of drug-
related hepatotoxicty, were not reported in the 912 subjects 
who received ER niacin up to 2000 mg concomitantly with 
simvastatin 20 to 40 mg over a period of up to 52 weeks. In 
the ER niacin clinical trial database, none of the 245 subjects 
receiving doses of 500 to 3000 mg over 17 weeks and 1% 
of 1028 subjects receiving ER niacin coformulated with 
lovastatin had persistent transaminase elevations  3 times 
the upper limit of normal.17 Serum alanine aminotransferase 
should be monitored every 6 to 12 weeks during the ﬁ  rst 
6 to 12 months of niacin treatment, and every 6 months 
thereafter. The dose of ER niacin should not exceed 2 g/day 
since serious hepatoxicity and fulminant liver failure have 
been reported with doses of slow or sustained-release nia-
cin  1.5 g/day.16
No safety data are available for ER niacin used with 
the highest dose (80 mg) of simvastatin. Slightly higher 
rates of persistent transaminases elevations occur at the 
highest dose of simvastatin, with 0.9% having persistent 
transaminase elevations with 40 mg and 2.1% with 80 mg 
over 12 months of treatment.21 In long-term morbidity/
mortality studies, persistent transaminase elevations for 
simvastatin monotherapy are uncommon but dose-related. 
Moderate dose simvastatin (20–40 mg) has a rate of  0.5% 
over a 5-year period, while simvastatin 80 mg has a rate 
closer to 1%.22 Excessive alcohol intake or a past history 
of liver disease may also increase the risk of transaminase 
elevations with simvastatin. Randomized trials have not Vascular Health and Risk Management 2009:5 36
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reported any difference in rates of clinical hepatitis (jaundice 
or other symptoms), hepatic failure, or other evidence 
of hypersensitivity with simvastatin or any other statin 
compared to placebo.23
Muscle
The most common form of myotoxicity related to lipid-modifying 
drugs is myalgia (muscle pain, weakness, or cramps) with 
normal creatine phosphokinase (CK) levels. Clinically 
important myopathy is characterized by muscle symptoms 
and evidence of muscle damage (elevated CK levels), 
which in its most severe form, rhabdomyolysis, has 
more extensive muscle damage and is usually associated 
with renal impairment.24 In the 912 subjects in the ER 
niacin–simvastatin Simcor® clinical trial database, no cases 
of myopathy, rhabdomyolysis, or CK elevations  10 times 
the upper limit of normal were reported over a period as 
long as 52 weeks (Table 2). Myalgias were slightly more 
likely in those receiving simvastatin 40 mg combined with 
ER niacin 2000 mg with (2%) than with ER niacin 1000 mg 
(0.9%). No cases of rhabdomyolysis and 1 case of myopa-
thy were reported in 1079 subjects treated with ER niacin 
and lovastatin 40 mg over a period of up to 2 years.25 Rare 
cases of rhabdomyolysis have been associated with statins 
used concomitantly with niacin  1 g in the Food and Drug 
Administration Adverse Event Reporting Database.26 Indeed, 
the safety of ER niacin and a statin appears comparable with 
the safety of each drug used alone.
In the over 20,000 subjects in the 5-year Heart Protection 
Study (HPS), about 6% of subjects reported muscle 
symptoms at a given visit in both the simvastatin and placebo 
groups.27 However, this rate may be lower than experienced 
in clinical practice since 30% of subjects did not proceed 
to randomization following a 5-week active run-in period. 
Myopathy and rhabdomyolysis are very rare with simvastatin 
monotherapy. In the clinical trial database for simvastatin, 
41,050 subjects were treated with simvastatin, of which 
26,747 (60%) were treated more than 4 years. Although very 
uncommon, dose-related increases in the risk of myopathy 
and rhabdomyolysis occurred at a rate of 0.02% for 20 mg, 
0.08% for 40 mg, and 0.53% for 80 mg.21 There were 10 cases 
of myopathy/rhabdomyolysis in the 10,269 subjects allocated 
to simvastatin (0.1%) in HPS, 4 of whom were  65 years; 
4 cases of myopathy occurred in the placebo group (0.04%).27 
It should be emphasized that participants in clinical trials 
are carefully selected to minimize the potential for toxic-
ity. Much higher rates of rhabdomyolysis have been found 
when simvastatin has been used in patients with multiple 
risk factors for myopathy, including concomitant use with 
gemﬁ  brozil, advanced age, impaired renal function, and 
serious comorbid conditions.28
Inhibitors of CYP3A4 shown to increase serum simvas-
tatin levels include itraconazole, ﬂ  uconazole, erythromycin, 
clarithromycin, cyclosporine, danazol, diltiazem, verapamil, 
amiodarone, grapefruit juice, HIV protease inhibitors, 
and some antidepressants. In 25,248 patients treated with 
simvastatin and verapamil, the incidence of myopathy was 
0.63% compared to 0.061% in those taking simvastatin 
with another calcium channel blocker.21 The ﬁ  brate gem-
ﬁ  brozil (Lopid®, Pﬁ  zer, New York, NY; generic, Watson 
Pharamceutical, Corona, CA) inhibits the glucuronidation of 
statins to inactive forms.29 Gemﬁ  brozil increases the blood 
levels of all statins, with the exception of atorvastatin.30,31 
Fenoﬁ  brate (Tricor®, Abbott, North Chicago, IL; Loﬁ  bra®, 
Gate, Sellerville, PA; Triglide®, Sciele, Atlanta, GA) is a 
weaker inhibitor of glucuronidation and appears to have a 
lower rate of serious muscle effects when used concomitantly 
with a statin.
Other adverse effects of ER niacin
Niacin may worsen insulin resistance, especially in those with 
impaired fasting glucose or abnormal glucose tolerance.16 
Patients with fasting glucose levels 100 to 125 mg/dL 
may be at increased risk of developing diabetes on niacin 
and should be encouraged to adhere to healthy lifestyle 
pattern and undergo careful monitoring. However, since 
idiosyncratic elevations of glucose may occur in those with 
normal glucose levels, fasting glucose should be monitored 
after each dose titration and annually thereafter. Niacin 
at a dose of approximately 2000 mg has been shown to 
reduce coronary heart disease (CHD) events in patients 
with diabetes but may require intensiﬁ  cation of diabetic 
therapy if glucose control worsens.32,33 This dose of niacin 
has also been shown to reduce CHD in those with metabolic 
syndrome, although diabetes incidence was not reported.34 
It is of concern that earlier onset of diabetes may increase 
long-term cardiovascular risk and so long-term trials are 
needed to evaluate the cost versus beneﬁ  t in insulin resistant 
subjects.
Niacin has several other uncommon adverse effects.16 
Niacin raises uric acid 5% to 15%. Gout is a relative 
contraindication to niacin, although allopurinol can be 
considered for patients with a history of gout whose serum 
uric acid levels exceed 10 mg/dL. Niacin more than doubles 
the risk of atrial ﬁ  brillation and should be avoided in patients 
with intermittent atrial ﬁ  brillation or other atrial arrhythmias. Vascular Health and Risk Management 2009:5 38
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However, niacin is an option for patients with established 
atrial ﬁ  brillation or ventricular arrhythmias. Other adverse 
effects of niacin include upper gastrointestinal bleeding 
(niacin is contraindicated only in patients with active peptic 
ulcer disease), blurred vision (cystoid macular degeneration 
reported with niacin  3 g), and mildly decreased platelet 
counts.
Clinical context for ER niacin–
simvastatin use
Statins are the lipid-modifying drugs of choice for 
cardiovascular risk reduction. Extensive clinical trial 
data from over 90,000 participants in long-term trials has 
shown that for each 38 mg/dL reduction in low-density 
lipoprotein cholesterol (LDL-C), statins reduce the risk 
of CHD by 23% and stroke by 17%.35 Moreover, statins 
are quite safe in properly selected patients.22 Similar mag-
nitudes of CHD risk reduction occur with other therapies 
that primarily lower LDL-C.36 What is the potential role 
of simvastatin–niacin ﬁ  xed dose formulations within this 
context?
LDL-C
In order to reach the aggressive LDL-C goals of  100 mg/dL 
(2.59 mmol/L) or  70 mg/dL (1.81 mmol/L) identiﬁ  ed in 
recent guidelines,37,38 the majority of patients will require 
not only a high-dose statin, which may lower LDL-C by 
up to 50% to 60%, but the addition of intensive lifestyle 
changes and/or or one or more drugs. In the Treating to 
New Targets Trial, on atorvastatin 10 mg more than half 
of subjects had an LDL-C  100 mg/dL and on atorvastatin 
80 mg, more than half had an LDL-C  77 mg/dL.39 Only 2 
statins lower LDL-C by  50%: atorvastatin 40 to 80 mg/day 
and rosuvastatin 20 to 40 mg/day.40, 41 Options for achieving 
an additional approximate 15% reduction in LDL-C include 
quadrupling the statin dose, or adding niacin 2 g, bile acid 
sequestrants, or ezetimibe 10 mg.1,6,17,25,42,43 Fibrates have 
variable effects on LDL-C, and may increase levels in 
patients with elevated triglyceride levels.44–46 In general, 
fenoﬁ  brate appears to more effectively lower LDL-C than 
gemﬁ  brozil, which also has serious safety concerns when 
used with a statin.
The Ezetimibe and Simvastatin in Hypercholesterolemia 
Enhances Atherosclerosis Regression (ENHANCE) trial 
recently brought into question whether the additional LDL-C 
reduction from ezetimibe will translate into a reduction in 
cardiovascular events. In ENHANCE, ezetimibe 10 mg added 
to high dose simvastatin therapy had no signiﬁ  cant effect 
on carotid intimal medial thickness (CIMT) over a 2-year 
period in 720 subjects with familial hypercholesterolemia 
(FH).47 ENHANCE differed in 2 important ways from the 
earlier Atorvastatin versus Simvastatin on Atherosclerosis 
Progression (ASAP) trial which demonstrated regression 
with atorvastatin 80 mg compared to simvastatin 40 mg 
in FH subjects.48 In ASAP, subjects were required to have 
a baseline CIMT  0.7 mm and few had been treated with 
aggressive LDL-C-lowering therapy. As would be expected 
after ASAP, which was conducted by the same investigators, 
80% of subjects in ENHANCE received prior statin therapy 
and were most likely treated with high dose statins if not 
ezetimibe as well. Long-term statin therapy stabilizes plaque 
by depleting lipid content without changing plaque volume.49 
In the 20% of ENHANCE subjects who were statin naïve 
at baseline, there was evidence of less CIMT progression in 
those receiving ezetimibe. Two major conclusions can be 
drawn from ENHANCE. First, ENHANCE demonstrated 
the success of cholesterol-lowering treatment. ENHANCE 
subjects (mean age 46) had baseline CIMT levels similar to 
that of an average 32-year-old male with an untreated LDL-C 
of 134 mg/dL.50 Second, lowering LDL-C by another 17% 
over a 2-year period in subjects with stabilized plaque had 
little effect. The ﬁ  ndings in ENHANCE are similar to those 
in the ASAP trial after 2 additional years of follow-up.51 For 
these reasons, Merck cancelled a carotid IMT trial of its ER 
niacin–simvastatin–laropiprant product.52
The Simvastatin and Ezetimibe in Aortic Stenosis 
(SEAS) trial failed to meet its primary endpoint of a reduc-
tion aortic valve disease events and major cardiovascular 
events.53 Simvastatin 40 mg/ezetimibe 10 mg was compared 
to placebo over 4 years in 1873 subjects with asymptomatic 
mild to moderate stenosis who did not have an indica-
tion for statin therapy. A 22% reduction in the secondary 
endpoint of major atherosclerotic events was found with 
ezetimibe–simvastatin, which lowered LDL-C by 61%. 
However, more cancers were observed in the ezetimibe-
simvastatin (n = 105, 11.1%) than in the placebo group 
(n = 70, 7.5%; p = 0.01), and more cancer deaths (n = 39, 
4.1% vs n = 23, 2.5%; p = 0.05. No particular type of cancer 
was predominant. A meta-analysis of 2 additional ongoing 
ezetimibe–simvastatin versus simvastatin monotherapy trials 
(SHARP and IMPROVE-IT, total N = 20,617) found similar 
rates of cancer in the 2 groups (n = 313 vs 326, respectively; 
risk ratio 0.96, 95% CI 0.82–1.12, p = 0.61).54 The mean 
follow-up of subjects in these trials is less than in SEAS. 
In light of the controversies surrounding the efﬁ  cacy and 
safety of ezetimibe, ER niacin remains a reasonable choice Vascular Health and Risk Management 2009:5 39
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for additional LDL-C and non-HDL reduction in patients 
receiving statin therapy.
Non-HDL-C
The ATP III guidelines identiﬁ  ed non-HDL-C as the second 
target of therapy in patients with triglyceride levels between 
200 and 500 mg/dL (2.26–5.64 mmol/L). Non-HDL-C is 
calculated by subtracting HDL-C from total cholesterol and 
is a measure of circulating atherogenic Apo B-containing 
apolipoproteins – LDL-C, VLDL-C and intermediate density 
lipoprotein cholesterol. The non-HDL-C goal is 30 mg/dL 
(0.78 mmol/L) higher than the LDL-C goal. Non-HDL-C is 
a more accurate predictor of cardiovascular risk than LDL-C, 
and closely correlates with Apo B levels in patients receiving 
statin therapy.55 Reductions in non-HDL-C from add-on drug 
therapies to background statin treatment are about 6% from 
doubling the statin dose, 12% from ezetimibe 10 mg, and 
highly variable for ﬁ  brates (+2% to −18%).6,42,44,45 Bile acid 
sequestrants are less effective for lowering non-HDL-C (−5% 
to 8%) due to their VLDL-C raising effects.43 In contrast, the 
addition of ER niacin 2000 mg to simvastatin can decrease 
non-HDL-C by 16% to 28%, in large part due to the increases 
in HDL-C.13,25
HDL-C and triglycerides  500 mg/dL
An HDL-C level  40 mg/dL (1.04 mmol/L) was deﬁ  ned 
as a risk factor for cardiovascular disease by ATP III on 
the basis of epidemiologic data. However, a treatment goal 
was not identiﬁ  ed due to the lack of clinical trial evidence 
that pharmacologically raising HDL-C results in a reduction 
in cardiovascular risk. The method by which HDL-C is 
raised may be important. Development of torcetrapib was 
discontinued due to an excess of deaths in a large morbidity/
mortality trial despite a 72% increase in HDL-C and a 25% 
decrease in LDL-C with torcetrapib over atorvastatin therapy 
alone.56 Adverse off-target effects on the renin-angiotensin 
system and blood pressure elevations have been implicated, 
although an adverse effect of cholesteryl ester transfer protein 
inhibition or other effects cannot be excluded.
Similarly, a triglyceride level  150 mg/dL (1.69 mmol/L) 
was deﬁ  ned as optimal on the basis of epidemiologic data 
but a treatment target for drug therapy to prevent 
cardiovascular disease was not identified. ATP III did 
deﬁ  ne a triglyceride goal of  500 mg/dL (5.64 mmol/L). 
to prevent pancreatitis and its complications in patients with 
severe hypertriglyceridemia deﬁ  ned as fasting triglycer-
ides  500 mg/dL. Although triglyceride levels  150 mg/dL 
have been associated with increased cardiovascular risk, 
much of the excess risk disappears after adjustment for low 
HDL-C and insulin resistance. Clinical trials comparing 
high- to moderate-dose statin therapy have not found the 
additional 20% to 25% reduction in triglycerides added 
to the risk reduction expected from the degree of LDL-C 
reduction,35,39,57 nor have trials of fenoﬁ  brate and gemﬁ  brozil 
found a correlation between triglyceride-lowering and 
cardiovascular event reduction.58
“Residual risk” is a term that has been used to describe 
the fact that patients who have achieved their LDL-C and 
non-HDL-C goals on statin therapy may still experience a 
cardiovascular event. These patients often have low HDL-C 
and elevated levels of triglycerides levels, LDL-C particles, 
and apo B. While levels of HDL-C and triglycerides 
remain predictive of cardiovascular risk in patients with 
LDL-C levels at goal, it is not entirely clear whether the 
HDL-C increases or triglyceride decreases from drug therapy 
contribute substantial additional beneﬁ  t beyond that expected 
from LDL-C lowering.36,59 An evidence-based strategy has 
yet to be determined for these patients. It should be realized, 
however, that residual lipid abnormalities are also reﬂ  ective 
of the inﬂ  ammatory state of insulin resistance, and thus 
may be markers rather than causal factors for the increased 
cardiovascular risk observed in these patients.60
Triglycerides  500 mg/dL
In those with triglyceride levels  500 mg/dL, prevention 
of pancreatitis is the primary objective. Once triglycerides 
are  500 mg/dL, attention can then turn to addressing 
cardiovascular prevention by lowering LDL-C and 
non-HDL-C.15 In those with severe hypertriglyceridemia, 
a triglyceride treatment goal of  500 mg/dL has been 
established for the purpose of preventing pancreatitis. Once 
it has been determined that the patient fasted for at least 
8 hours prior to obtaining the blood sample for triglyceride 
measurement, secondary causes of hypertriglyceridemia 
should be evaluated since triglyceride levels usually fall 
to  500 mg/dL once these conditions have been treated. 
Particular attention should be paid to detecting undiagnosed 
or poorly controlled diabetes or hypothyroidism. All patients 
should see a dietitian for counseling on a diet very low in fat 
( 15%) and reﬁ  ned carbohydrates, and obese patients should 
be counseled to lose weight. When triglyceride levels exceed 
1000 mg/dL, a triglyceride-lowering drug is usually started 
simultaneously with diet and lifestyle changes. Fibrates are 
considered ﬁ  rst-line therapy and lower triglycerides by 20% 
to 50%.38 Concentrated omega-3 ﬁ  sh oils with 3 to 4 g of 
eicosopentanoic and docohexanoic acids are an excellent Vascular Health and Risk Management 2009:5 40
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second-line therapy with a similar efﬁ  cacy proﬁ  le to ﬁ  brates, 
and may be safer when combined with higher dose statin 
therapy.61 ER niacin can be considered as add-on therapy or in 
those unable to tolerate ﬁ  brates. No efﬁ  cacy data are available 
for ER niacin used in patients with triglycerides exceeding 
500 mg/dL, but in those with triglyceride levels exceeding 
200 mg/dL, 25% to 35% reductions in triglycerides were 
obtained above those obtained with simvastatin. Statins 
also lower triglycerides in a dose-dependent manner, with 
25% to 30% reductions in triglycerides from atorvastatin 
40 to 80 mg and rosuvastatin 20 to 40 mg.42 Simvastatin, 
however, has lesser effects on triglycerides, with 15% to 20% 
reductions with simvastatin 40–80 mg. Ezetimibe has modest 
triglyceride-lowering effects. Bile acid sequestrants are 
contraindicated in these patients since marked exacerbation 
of hypertriglyceridemia may occur. Once triglyceride 
levels are  500 mg/dL, attention can then turn to achieving 
LDL-C and non-HDL-C goals to reduce cardiovascular risk, 
as described above.
Lp(a)
The addition of ER niacin 200 mg lowered Lp(a) by 17% 
to 25% more than simvastatin alone. The signiﬁ  cance of 
this is unclear. Very high levels of Lp(a) are associated 
with increased cardiovascular risk in some but not all 
populations, nor has not been shown that reducing Lp(a) 
reduces cardiovascular risk.62
Cardiovascular endpoint studies
The addition of niacin or fibrates to statin therapy has 
been advocated by some to normalize residual HDL-C 
and triglyceride abnormalities. However, no clinical trial 
evidence is yet available from long-term morbidity/mortality 
trials to determine whether pharmacologic strategies directed 
to these abnormalities are additive to lowering LDL-C and 
non-HDL-C with statin therapy. Extensive clinical trial 
evidence has shown that simvastatin and other statins lower 
the risk of heart attack and stroke in direct proportion to the 
magnitude of LDL-C reduction.35 The only randomized, 
controlled trial, of niacin monotherapy, the Coronary Drug 
Project, reported a 17% reduction in coronary heart disease 
events over 6.2 years with approximately 2 g of niacin.63 It 
should be noted this relative reduction in risk is about what 
would be expected from a 15% reduction in LD-C with niacin 
2 g, the average dose in the trial.
Several trials have evaluated the effect of ER or 
sustained-release niacin combined with a statin or colestipol 
on surrogate endpoints of coronary angiographic progression 
or carotid IMT. Beneficial effects on angiographic 
progression or carotid IMT were observed over periods 
of 2 or more years.64–67 In the HDL and Atherosclerosis 
Treatment Trial (HATS), 160 subjects with CHD, low 
HDL-C, and normal LDL-C were randomized to placebo 
or a mean dose of simvastatin 13 mg and sustained-release 
niacin 2.4 g for 3 years.64 The niacin–simvastatin group had 
a 42% reduction in LDL-C and a 26% increase in HDL-C 
and experienced regression on coronary angiography along 
with a 92% reduction in CHD events.
The Arterial Biology for the Investigation of the 
Treatment Effects of Reducing Cholesterol (ARBITER)-2 
study was a 12 month carotid IMT study in 149 subjects 
that compared a statin to a statin with ER niacin 1000 mg 
added.68 Simvastatin  20 mg was the statin used by 93% 
of subjects. There were no differences in the non-HDL-C 
or LDL-C levels between the 2 groups, although HDL-C 
was increased by 21% and triglycerides were lowered an 
additional 8% in the niacin group (Table 1). The niacin 
group had no progression in carotid IMT versus progression 
in the group on statin monotherapy compared to baseline, 
although no signiﬁ  cant difference between the 2 groups was 
found at 1 year. A subset of 125 subjects continued into 
the ARBITER 3 trial and all were treated with ER niacin 
and a statin for another year.67 Among the subjects treated 
with ER niacin for 24 months, regression of carotid IMT 
was observed.
Few cardiovascular events were reported in these small 
surrogate endpoint trials, precluding any deﬁ  nitive conclusions 
regarding the value of niacin-related lipid changes other than 
LDL-C reduction for reducing cardiovascular risk. Reductions 
in coronary heart disease risk varied from 17% to 92%, although 
the 95% conﬁ  dence intervals were wide and included 1.0.
Several clinical trials are underway to evaluate the 
beneﬁ  t of ER niacin added to background statin therapy. 
Ongoing clinical trials include the AIM-HIGH trial, 
which will determine whether the addition of ER niacin to 
simvastatin will result in additional cardiovascular event 
reduction independent of the degree of LDL-C-lowering 
in subjects with established cardiovascular disease.8 The 
HPS-2 THRIVE trial will randomize 20,000 subjects with 
cardiovascular disease to aggressive LDL-C-lowering using 
simvastatin with or without ER niacin coformulated with 
laropiprant.5
Areas for future investigation
The large majority of subjects in the ER niacin–simvastatin 
database have been middle-aged. Since older individuals Vascular Health and Risk Management 2009:5 41
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are at the highest absolute risk of a coronary heart disease 
or stroke event, more studies of efficacy, safety, and 
tolerability in the elderly are needed.69 Notably, most ﬁ  rst 
cardiovascular events occur after age 75 in women. Efﬁ  cacy 
and safety studies are needed in other populations as well. 
Those with both diabetes and cardiovascular disease are at 
very high risk of a cardiovascular event and have the poten-
tial for the most absolute beneﬁ  t from very aggressive lipid 
management.70 Those with impaired fasting glucose and 
metabolic syndrome are also at increased cardiovascular 
risk, but may also be at increased risk of transitioning 
to diabetes with niacin. Furthermore, many patients will 
require the addition of another lipid-lowering agent to high 
dose statin therapy to achieve very aggressive LDL-C and 
non-HDL goals.
Conclusions
ER niacin combined with simvastatin provides an additional 
option for achieving LDL-C and non-HDL-C goals for 
cardiovascular prevention. The 2000 mg dose of ER niacin 
has the greatest beneﬁ  t for lowering LDL-C and non-HDL-C. 
ER niacin–simvastatin at both the 1000 and 2000 mg doses 
is effective for raising HDL-C and lowering triglycerides 
compared simvastatin monotherapy, although the additive 
benefit of these changes for reducing cardiovascular 
events remains to be determined. ER niacin–simvastatin is 
reasonably well-tolerated by most patients. The muscle and 
liver safety proﬁ  le of the combination appears to be similar 
to that of ER niacin and simvastatin used as monotherapy. 
Combination of ER niacin with simvastatin has the potential 
to be safer than some statin–ﬁ  brate combinations, although 
no head-to-head comparison have been performed. ER 
niacin has an increased rate of hyperglycemia, adverse 
gastrointestinal effects, and atrial arrhythmias that may 
alter the beneﬁ  t-risk ration in at-risk populations. Therefore, 
the efﬁ  cacy, safety and tolerability in the elderly, women, 
those with diabetes, and with the highest doses of statins are 
needed. Results of ongoing ER niacin morbidity/mortality 
trials are eagerly awaited.
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